Nama's AI scorecard currently rates Halozyme Therapeutics Buy (8.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is HALO's P/E ratio?

Halozyme Therapeutics trades at a trailing price-to-earnings ratio of 17.2.

When does HALO report earnings?

Halozyme Therapeutics's next scheduled report is on Feb 16, 2027. Analysts expect EPS of $2.61.

What is the HALO price target?

The median analyst price target from 9 analysts is $110.00, with a range of $79.00 – $130.00.

Is HALO Shariah compliant?

Nama's AAOIFI-style screen reads Halozyme Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Halozyme Therapeutics (HALO)

Healthcare · Biotechnology · NASDAQ

Halozyme Therapeutics (HALO) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $11.76B, a trailing price-to-earnings ratio of 17.2 and a free-cash-flow yield of 2.8%. Over the most recent reported fiscal year, revenue grew 37.5% and free cash flow per share fell 20.4%. Nama's AI scorecard rates it Buy, 8.1 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 8.1/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Leading · +62.0% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-22.7%

How far the last close sits under the highest price of the past five years.

Market cap	$11.76B
Trailing P/E	17.2
Price / book	82.2
Price / sales	7.1
FCF yield	2.8%
Dividend yield	—
Gross margin	82.4%
Operating margin	56.0%
Net margin	24.9%
Revenue growth (YoY)	+37.5%
Revenue growth (3-yr annual)	+28.4%
EPS growth (YoY)	-2.4%
FCF/share growth (YoY)	-20.4%
Beta	0.9
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

HALO earnings

Next report: Feb 16, 2027 (Q4 2026, EPS estimate $2.61). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$2.39	$2.36	+1.3%	—
Q2 2026	Aug 6, 2026	$2.28	$1.82	+25.3%	$481.00M
Q1 2026	May 11, 2026	$1.60	$1.52	+5.3%	$376.71M
Q4 2025	Feb 17, 2026	-$0.24	$2.20	-110.9%	$451.77M

HALO analyst price target

Median target $110.00 from 9 analysts, ranging $79.00 – $130.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live HALO data on Nama Insights →

Recent Congressional trades

Halozyme Therapeutics trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Oct 12, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Apr 7, 2026
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Apr 7, 2025
Josh Gottheimer	House	Sell	$1,001 - $15,000	Oct 3, 2024
Mark R Warner	Senate	Sell	$500,001 - $1,000,000	—

HALO FAQ

Is HALO a buy?: Nama's AI scorecard currently rates Halozyme Therapeutics Buy (8.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is HALO's P/E ratio?: Halozyme Therapeutics trades at a trailing price-to-earnings ratio of 17.2.
When does HALO report earnings?: Halozyme Therapeutics's next scheduled report is on Feb 16, 2027. Analysts expect EPS of $2.61.
What is the HALO price target?: The median analyst price target from 9 analysts is $110.00, with a range of $79.00 – $130.00.
Is HALO Shariah compliant?: Nama's AAOIFI-style screen reads Halozyme Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.